Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Artisan Partners Limited Partnership

Artisan Partners Limited Partnership lessened its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 2.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,053,709 shares of the life sciences company's stock after selling 23,466 shares during the quarter. Artisan Partners Limited Partnership owned about 0.66% of Illumina worth $140,807,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in ILMN. Versant Capital Management Inc grew its stake in shares of Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock valued at $32,000 after buying an additional 146 shares during the period. Golden State Wealth Management LLC acquired a new stake in Illumina during the fourth quarter worth $32,000. Assetmark Inc. raised its position in Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock valued at $44,000 after purchasing an additional 296 shares during the period. Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Illumina in the 4th quarter valued at $45,000. Finally, Lee Danner & Bass Inc. purchased a new position in shares of Illumina during the 4th quarter worth $48,000. Hedge funds and other institutional investors own 89.42% of the company's stock.

Wall Street Analyst Weigh In

ILMN has been the topic of a number of recent analyst reports. Hsbc Global Res cut shares of Illumina from a "strong-buy" rating to a "hold" rating in a research report on Friday, February 28th. Citigroup decreased their price objective on shares of Illumina from $130.00 to $90.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Canaccord Genuity Group dropped their target price on shares of Illumina from $135.00 to $115.00 and set a "hold" rating for the company in a report on Tuesday, March 11th. Barclays restated an "underweight" rating on shares of Illumina in a research note on Tuesday, March 11th. Finally, Stephens reaffirmed an "overweight" rating and issued a $156.00 price objective on shares of Illumina in a research note on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $140.90.

Remove Ads

Illumina Stock Down 2.8 %

Shares of Illumina stock traded down $2.28 during trading hours on Friday, hitting $80.00. The company had a trading volume of 1,526,373 shares, compared to its average volume of 2,212,008. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The company's 50-day moving average is $102.80 and its two-hundred day moving average is $126.81. The company has a market cap of $12.67 billion, a P/E ratio of -10.42, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. Illumina, Inc. has a twelve month low of $79.30 and a twelve month high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.